Stating that chemotherapy, which has been widely used since the 1950s, is still the main component of treatments in many cancer types today, Medical Oncology Specialist Prof. Dr. Nezih Meydan shared the following information:
“These classical treatments are usually organ specific (breast, lung, colon cancer, etc.) and consist of drugs with proven efficacy in numerous studies. However, the information obtained over the years about cancer development and molecular technological developments that help detect mutations that occur in this process are similar to cancer. This development made it necessary to make a classification from organ-specific definitions to molecular subtypes in some cancer types. Conversely, in some cases, in the presence of similar mutations even in tumors of different regions, the use of drugs developed against that particular mutation independent of the organ is similar “This has increasingly demonstrated that organ-independent molecular-targeted therapies can be effective in the presence of a particular mutation.”
CO-USE OF NEW DRUGS AND CLASSIC CHEMOTHERAPY DRUGS
Noting that the newly developed drugs give significant results when used together with classical chemotherapy drugs in some cases, Meydan said, “In some cases, significant efficacy results can be obtained when newly developed molecular-based drugs are used together with classical chemotherapy drugs. The development of technology has paved the way for a better understanding of the underlying molecular genetic processes, as well as the development of various drugs much faster than before. These drugs, which are specially produced against a known underlying disorder, are named with different names such as targeted drugs, rationally designed drugs and are referred to as smart drugs among the public. In addition to the extraordinary changes in the treatment method, effectiveness and disease process of some types of cancer, these drugs still have some problems.
Stating that the effectiveness of newly developed drugs is high, but resistance can develop after a while, Meydan said, “Developing technology facilitates the development of new molecules that are not affected by these resistance mechanisms. “In a sense, it offers personalized (individualized) treatment options apart from classical treatment approaches. These treatments have taken their place as standard treatments in many cancers such as lung, melanoma and breast today.”
GENETIC OR CELL CHANGE MUST HAVE BEEN DETECTED
Referring to other areas of use of genetic studies, Meydan said, “Although the standards and information are not yet fully determined, it is their use in order to find an additional treatment alternative in patients who have exhausted all effective treatment options. “As a result, targeted drugs are increasingly taking their place in the field of oncological treatment. For these drugs to be effective, a special genetic or cellular change must be detected. They have taken their place in treatment algorithms for many tumors and are still used in appropriate patients and situations.” used.